Kelai Pharmaceutical partners with Nutrasource to support drug development into natural compounds
US-based Kelai Pharmaceutical has hired Canada-based full service contract research organisation (CRO), Nutrasource Pharmaceutical and Nutraceutical Providers, to assist with their early stage drug growth programme, where they hope to establish drug candidates from botanical crops to develop prescribed drugs.
“Navigating the regulatory pathway for a new drug is no simple task. Kelai is happy to have an FDA regulatory partner with significant expertise in both natural compounds and pharmaceuticals to support us in plotting this course. This will let us be laserfocused on the most important tasks – minimising our risk and optimising our efforts from the earliest stages of development,” notes Dr. Jacqueline Jacques, CEO of Kelai Pharmaceutical.
Working with botanicals in a pharmaceutical capacity opens up many opportunities, due to the fact that botanicals start out as complex endogenous compounds. Many aspects of the plant might therefore produce the eventual drug candidate. However, this also makes it a fraught task as, although the medicinal properties of a plant may be well-known, they have not been used in a pharmaceutical context.
William Rowe, President and CEO of Nutrasource commented, “Nutrasource’s long-standing strategic positions in both nutrition and pharmaceutical scientific solutions were key factors in Kelai’s decision-making process. We are delighted to be serving Dr Jacques and her team in this capacity, bringing cutting edge botanicals and related technology down the pharmaceutical pathway.”
Pharmaceutical Industry news, analysis and insights